Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.47 |
| ▸ | HTT | P42858 | 2/20 | 0.47 |
| ▸ | LMNA | P02545 | 1/20 | 0.47 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.47 |
| ▸ | BCHE | P06276 | 3/20 | 0.47 |
| ▸ | POLB | P06746 | 3/20 | 0.46 |
| ▸ | MEN1 | O00255 | 2/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.41 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.40 |
| ▸ | MAPT | P10636 | 2/20 | 0.39 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.39 |
| ▸ | CLK1 | P49759 | 1/20 | 0.39 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL204159 | 0.92 | KMT2A (0.49) | ALDH1A1HTTLMNASMN1; SMN2BCHE | |
| SCHEMBL2709571 | 0.92 | HTT (0.51) | ALDH1A1HTTLMNASMN1; SMN2BCHE | |
| SCHEMBL20564258 | 0.89 | ALDH1A1 (0.59) | ALDH1A1HTTLMNASMN1; SMN2BCHE | |
| SCHEMBL2709340 | 0.86 | ALDH1A1 (0.46) | ALDH1A1HTTLMNASMN1; SMN2BCHE | |
| SCHEMBL671016 | 0.85 | ALDH1A1 (0.54) | ALDH1A1HTTLMNASMN1; SMN2BCHE | |
| SCHEMBL29642061 | 0.85 | ALDH1A1 (0.54) | ALDH1A1HTTLMNASMN1; SMN2BCHE | |
| SCHEMBL204433 | 0.85 | BCHE (0.47) | ALDH1A1HTTLMNASMN1; SMN2BCHE | |
| SCHEMBL2682720 | 0.84 | ALDH1A1 (0.47) | ALDH1A1HTTLMNASMN1; SMN2BCHE | |
| SCHEMBL2707298 | 0.80 | KMT2A (0.55) | ALDH1A1HTTLMNASMN1; SMN2POLB | |
| SCHEMBL2706301 | 0.79 | KDM4E (0.50) | ALDH1A1HTTLMNASMN1; SMN2BCHE |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8088788-B2 | Substituted fused[1,2] imidazo[4,5-c] ring compounds and methods | 3M INNOVATIVE PROPERTIES COMPANY (US) | 2012-01-03 | — | — | US | disclosed |
| US-20090221551-A1 | SUBSTITUTED FUSED[1,2] IMIDAZO[4,5C] RING COMPOUNDS AND METHODS | PFIZER INC. | 2009-09-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090221551-A1 | SUBSTITUTED FUSED[1,2] IMIDAZO[4,5C] RING COMPOUNDS AND METHODS | IL2, IFNG, IL4 | ALDH1A1 979/4885HTT 4747/4885LMNA 3320/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.